VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

CAR-T Meeting 2020 | The role of CAR T-cell therapy in DLBCL

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses the impact of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). CAR T-cell therapy represents an important and promising tool for patients that have failed previous treatment strategies. Dr Sureda reveals that a significant proportion of patients still relapse after CAR T-cell therapy and outlines the strategies to overcome this challenge. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter